Chemotherapeutics in Equine Practice.

This research article discusses the application of chemotherapy in treating various types of cancers in horses, with a particular emphasis on the treatment of skin tumors. The article points out that while there are potential risks and side effects to consider, chemotherapy could serve as a viable option for treating a variety of cancers.

Chemotherapy and its use in Equine Practice

The primary objective of this research article is to illustrate the use of chemotherapy in equine practice, primarily in treating cancerous cells in horses. It unpacks the use of such treatment methods by breaking it down into several key points:

• The use of systemic (intravenous) chemotherapy is generally limited to managing lymphoma in horses.
• Cytotoxic drugs, a type of drug used in chemotherapy that kill or slow the growth of various cells, are common in the treatment of accessible skin tumors in horses. These drugs can be applied topically in the form of ointments or injected directly into the lesion.
• The potential for severe adverse side effects realigns the need for caution when employing these chemotherapeutic drugs. Risks associated with chemotherapy in equine practices include a range of symptoms from mild nausea to life-threatening infections due to lowered immune system function.

Potential Risks and Precautions

The article emphasizes the need for extreme caution during the preparation, handling, administration, and disposal of these cytotoxic drugs due to their carcinogenic, mutagenic, and teratogenic properties. Here are the primary concerns:

• Carcinogenic properties: There is a potential risk of these drugs causing cancer, either in the horses being treated or potentially in the humans handling and administering the drugs.
• Mutagenic properties: These medications could cause genetic mutations at a cellular level, which could potentially lead to cancer.
• Teratogenic properties: The possibility also exists that these drugs could cause disruption to embryonic or fetal development, leading to birth defects.

As such, the paper stresses the need for medical professionals to handle cytotoxic drugs with the utmost care to minimize these potential risks. These dangers underline the importance of safety protocols in protecting both the patients and those providing the treatment.